114 related articles for article (PubMed ID: 22931339)
1. Anti-CD20 antibody therapy for B-cell lymphomas.
El Fassi D; Hegedüs L; Nielsen CH
N Engl J Med; 2012 Aug; 367(9):877; author reply 878. PubMed ID: 22931339
[No Abstract] [Full Text] [Related]
2. Anti-CD20 antibody therapy for B-cell lymphomas.
Calcagno A; Rostagno R; Di Perri G
N Engl J Med; 2012 Aug; 367(9):877-8; author reply 878. PubMed ID: 22931340
[No Abstract] [Full Text] [Related]
3. Anti-CD20 antibody therapy for B-cell lymphomas.
Taylor RP; Lindorfer MA; Zent CS
N Engl J Med; 2012 Aug; 367(9):876-7; author reply 878. PubMed ID: 22931338
[No Abstract] [Full Text] [Related]
4. Anti-CD20 antibody therapy for B-cell lymphomas.
Maloney DG
N Engl J Med; 2012 May; 366(21):2008-16. PubMed ID: 22621628
[No Abstract] [Full Text] [Related]
5. Intestinal lymphoma perforations as a consequence of highly effective anti-CD20 antibody therapy.
Kollmar O; Becker S; Schilling MK; Maurer CA
Transplantation; 2002 Feb; 73(4):669-70. PubMed ID: 11889454
[No Abstract] [Full Text] [Related]
6. [Rituximab and hematological malignancy].
Hatake K; Mishima Y; Terui Y
Nihon Rinsho; 2004 Jul; 62(7):1321-4. PubMed ID: 15283150
[TBL] [Abstract][Full Text] [Related]
7. [Clinical observation of Rituximab in a CD20+B non-Hodgkin's lymphoma].
Hao LC; Zhang LZ
Zhonghua Er Ke Za Zhi; 2003 Aug; 41(8):627. PubMed ID: 14744396
[No Abstract] [Full Text] [Related]
8. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
[TBL] [Abstract][Full Text] [Related]
9. Preclinical study of Ublituximab, a Glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas.
Ben Abdelwahed R; Donnou S; Ouakrim H; Crozet L; Cosette J; Jacquet A; Tourais I; Fournès B; Gillard Bocquet M; Miloudi A; Touitou V; Daussy C; Naud MC; Fridman WH; Sautès-Fridman C; Urbain R; Fisson S
Invest Ophthalmol Vis Sci; 2013 May; 54(5):3657-65. PubMed ID: 23611989
[TBL] [Abstract][Full Text] [Related]
10. Translational medicine in action: anti-CD20 therapy in lymphoma.
Lim SH; Levy R
J Immunol; 2014 Aug; 193(4):1519-24. PubMed ID: 25086174
[TBL] [Abstract][Full Text] [Related]
11. Action and resistance of monoclonal CD20 antibodies therapy in B-cell Non-Hodgkin Lymphomas.
Pérez-Callejo D; González-Rincón J; Sánchez A; Provencio M; Sánchez-Beato M
Cancer Treat Rev; 2015 Sep; 41(8):680-9. PubMed ID: 26045227
[TBL] [Abstract][Full Text] [Related]
12. New monoclonal antibody approved as lymphoma therapy.
Am J Health Syst Pharm; 1998 Jan; 55(2):110. PubMed ID: 9465971
[No Abstract] [Full Text] [Related]
13. Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma.
Roguedas AM; Watier H; Paintaud G; de Muret A; Vaillant L; Machet L
Br J Dermatol; 2005 Mar; 152(3):541-4. PubMed ID: 15787825
[TBL] [Abstract][Full Text] [Related]
14. Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue.
Hohloch K; Sahlmann CO; Lakhani VJ; Wulf G; Glass B; Hasenkamp J; Meller J; Riggert J; Trümper L; Griesinger F
Ann Hematol; 2011 Nov; 90(11):1307-15. PubMed ID: 21360108
[TBL] [Abstract][Full Text] [Related]
15. [Resistance to rituximab and CD20 mutation].
Terui Y; Hatake K
Nihon Rinsho; 2007 Jan; 65 Suppl 1():416-23. PubMed ID: 17474440
[No Abstract] [Full Text] [Related]
16. [First monoclonal antibody accepted for cancer therapy].
Itälä M
Duodecim; 1998; 114(6):509, 511. PubMed ID: 11466914
[No Abstract] [Full Text] [Related]
17. [Current possibilities for treatment for hepatitis C virus-induced cryoglobulinemic vasculitis and B-cell lymphoma].
Ignatova TM; Mukhin NA
Ter Arkh; 2012; 84(11):81-8. PubMed ID: 23252255
[TBL] [Abstract][Full Text] [Related]
18. Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better?
Freeman CL; Sehn L
Curr Oncol Rep; 2018 Nov; 20(12):103. PubMed ID: 30483893
[TBL] [Abstract][Full Text] [Related]
19. Rituximab-related urticarial reaction in a patient treated for primary cutaneous B-cell lymphoma.
Errante D; Bernardi D; Bianco A; De Nardi S; Salvagno L
Ann Oncol; 2006 Nov; 17(11):1720-1. PubMed ID: 16731537
[No Abstract] [Full Text] [Related]
20. Immunotherapy for low-grade non-hodgkin secondary lymphoma of the orbit.
Esmaeli B; Murray JL; Ahmadi MA; Naderi A; Singh S; Romaguera J; White CA; McLaughlin P
Arch Ophthalmol; 2002 Sep; 120(9):1225-7. PubMed ID: 12215104
[No Abstract] [Full Text] [Related]
[Next] [New Search]
